Hui Li, Lei Nie, Tiecheng Zhang, Ziwei Chen, Shipei Gao
{"title":"孟鲁司特联合布地奈德雾化吸入治疗儿童变应性鼻炎和哮喘的疗效及对儿童炎症反应的影响。","authors":"Hui Li, Lei Nie, Tiecheng Zhang, Ziwei Chen, Shipei Gao","doi":"10.18502/ijaai.v24i3.18677","DOIUrl":null,"url":null,"abstract":"<p><p>Studies have investigated montelukast and budesonide aerosol inhalation for treating allergic rhinitis (AR) and bronchial asthma (BA) in children. However, there are significant variations in dosage and duration of administration. This research evaluated the efficacy in children with AR and BA and analyzed montelukast's impact on the inflammatory response. This retrospective cohort study involved 100 children with AR and BA who were admitted to \"Baoding Hospital, Beijing Children's Hospital Affiliated with the Capital Medical University\" from October 2022 to September 2023. They were divided into a budesonide group (budesonide n=50) and a combination group (montelukast and budesonide, n=50). Comparisons were made between the two groups in terms of clinical efficacy, severity scores of AR and BA before and after treatment, inflammatory indicators (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)), pulmonary function indicators (forced expiratory volume in the first second (FEV1), peak expiratory flow rate (PEF)), and adverse reactions. After treatment, the severity scores of AR and BA in the combination group were 4.00±0.93 points and 2.64±0.56 points, which were lower than those in the budesonide group (5.14±0.66 points and 3.31±0.65 points, respectively). The total response rate of the combination group (96.00%) was higher than that of the budesonide group (80.00%). The levels of IL-6 and TNF-α in the combination group were lower than those in the budesonide group, and the levels of FEV1 and PEF in the combination group were higher than those in the budesonide group. Mometasone combined with budesonide shows good treatment effects in children with AR and BA.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":"24 3","pages":"268-276"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Montelukast and Budesonide Aerosol Inhalation in the Treatment of Allergic Rhinitis and asthma in Children and Its Effect on the Inflammatory Response of Children.\",\"authors\":\"Hui Li, Lei Nie, Tiecheng Zhang, Ziwei Chen, Shipei Gao\",\"doi\":\"10.18502/ijaai.v24i3.18677\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Studies have investigated montelukast and budesonide aerosol inhalation for treating allergic rhinitis (AR) and bronchial asthma (BA) in children. However, there are significant variations in dosage and duration of administration. This research evaluated the efficacy in children with AR and BA and analyzed montelukast's impact on the inflammatory response. This retrospective cohort study involved 100 children with AR and BA who were admitted to \\\"Baoding Hospital, Beijing Children's Hospital Affiliated with the Capital Medical University\\\" from October 2022 to September 2023. They were divided into a budesonide group (budesonide n=50) and a combination group (montelukast and budesonide, n=50). Comparisons were made between the two groups in terms of clinical efficacy, severity scores of AR and BA before and after treatment, inflammatory indicators (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)), pulmonary function indicators (forced expiratory volume in the first second (FEV1), peak expiratory flow rate (PEF)), and adverse reactions. After treatment, the severity scores of AR and BA in the combination group were 4.00±0.93 points and 2.64±0.56 points, which were lower than those in the budesonide group (5.14±0.66 points and 3.31±0.65 points, respectively). The total response rate of the combination group (96.00%) was higher than that of the budesonide group (80.00%). The levels of IL-6 and TNF-α in the combination group were lower than those in the budesonide group, and the levels of FEV1 and PEF in the combination group were higher than those in the budesonide group. Mometasone combined with budesonide shows good treatment effects in children with AR and BA.</p>\",\"PeriodicalId\":14560,\"journal\":{\"name\":\"Iranian journal of allergy, asthma, and immunology\",\"volume\":\"24 3\",\"pages\":\"268-276\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian journal of allergy, asthma, and immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18502/ijaai.v24i3.18677\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of allergy, asthma, and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18502/ijaai.v24i3.18677","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
Effect of Montelukast and Budesonide Aerosol Inhalation in the Treatment of Allergic Rhinitis and asthma in Children and Its Effect on the Inflammatory Response of Children.
Studies have investigated montelukast and budesonide aerosol inhalation for treating allergic rhinitis (AR) and bronchial asthma (BA) in children. However, there are significant variations in dosage and duration of administration. This research evaluated the efficacy in children with AR and BA and analyzed montelukast's impact on the inflammatory response. This retrospective cohort study involved 100 children with AR and BA who were admitted to "Baoding Hospital, Beijing Children's Hospital Affiliated with the Capital Medical University" from October 2022 to September 2023. They were divided into a budesonide group (budesonide n=50) and a combination group (montelukast and budesonide, n=50). Comparisons were made between the two groups in terms of clinical efficacy, severity scores of AR and BA before and after treatment, inflammatory indicators (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)), pulmonary function indicators (forced expiratory volume in the first second (FEV1), peak expiratory flow rate (PEF)), and adverse reactions. After treatment, the severity scores of AR and BA in the combination group were 4.00±0.93 points and 2.64±0.56 points, which were lower than those in the budesonide group (5.14±0.66 points and 3.31±0.65 points, respectively). The total response rate of the combination group (96.00%) was higher than that of the budesonide group (80.00%). The levels of IL-6 and TNF-α in the combination group were lower than those in the budesonide group, and the levels of FEV1 and PEF in the combination group were higher than those in the budesonide group. Mometasone combined with budesonide shows good treatment effects in children with AR and BA.
期刊介绍:
The Iranian Journal of Allergy, Asthma and Immunology (IJAAI), an international peer-reviewed scientific and research journal, seeks to publish original papers, selected review articles, case-based reviews, and other articles of special interest related to the fields of asthma, allergy and immunology. The journal is an official publication of the Iranian Society of Asthma and Allergy (ISAA), which is supported by the Immunology, Asthma and Allergy Research Institute (IAARI) and published by Tehran University of Medical Sciences (TUMS). The journal seeks to provide its readers with the highest quality materials published through a process of careful peer reviews and editorial comments. All papers are published in English.